CHIRON VISION FILES U.S. FDA APPLICATION TO MARKET DRUG DELIVERY IMPLANT FOR TREATMENT OF CMV RETINITIS; Signs Supply and Co-promotion Collaboration with Roche.
Linked as:
Extract
CHIRON VISION FILES U.S. FDA APPLICATION TO MARKET DRUG DELIVERY IMPLANT FOR TREATMENT OF CMV RETINITIS; Signs Supply and Co-promotion Collaboration with Roche.
EMERYVILLE, Calif. and NUTLEY, N.J.--(BUSINESS WIRE)-- July 5, 1995--Chiron Corporation (NASDAQ:CHIR) and Hoffmann-La Roche announced today that Chiron's ophthalmic business, Chiron Vision, has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) to market Vitrasert(TM), its intraocular implant which delivers ganciclovir directly to the eye for treatment of cytomegalovirus (CMV) retinitis. CMV retinitis is the most common opport...
See the full content of this document
Sponsored links
